A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
This phase I trial studies the side effects and best dose of anti-inducible T-cell
co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral
T-cell lymphoma follicular variant or angioimmunblastic T-cell lymphoma that has returned
after a period of improvement (relapsed) or has not responded to previous treatment
(refractory). Monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may
block cancer growth in different ways by targeting certain cells.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society